Alvotech (ALVO) shareholders
ALVONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ALVOW
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 3/30
$4.55+0.18 (+4.12%)
Close on Nov 18, 2026Market cap $1.42BP/E 45.5Yield –
Ownership
Who owns Alvotech's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Celtic Lux Holdings S.a r.l. Joint filing with Celtic Holdings S.C.A. (27.50%) | 107,450,988 | 27.50% | 13D (active) amendment | Jun 26, 2026 |
| Floki GP S.a r.l. Joint filing with Aztiq Pharma Partners S.a r.l. (33.30%), Aztiq Fund I SCSp (33.30%) | 103,849,420 | 33.30% | 13D (active) amendment | Dec 17, 2025 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
6M shares short
Days to cover
8.3
At 1M shares a day
Change since last report
-2.8%
From 6M shares
Short volume, 20 days
44.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alvotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 123,565 shares on Aug 26, 2026 over the last 90 days.
See a number that looks wrong?